Pazopanib/Pazopanib (Pazopanib) effects and efficacy

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential anti-tumor activity. Pazopanib was developed by GlaxoSmithKline and was approved by the FDA on October 19 in 2009. Pazopanib is an antineoplastic agent indicated for the treatment of patients with advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma who have received chemotherapy.

Pazopanib is a second-generation multi-target tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors-1, -2 and -3, Platelet-derived growth factor receptor-α, platelet-derived growth factor receptor-β and c-kit. These receptor targets are part of the angiogenic pathway, which promotes the formation of tumor blood vessels for tumor survival and growth. Pazopanib is a synthetic indazolylpyrimidine with a steady-state concentration greater than 15 μg/ml. This concentration is sufficient to observe maximal inhibition of VEGFR2 phosphorylation and some antitumor activity (the concentration required to inhibit the receptor is 0.01 - 0.084 μmol/L). Reduced tumor blood flow, increased tumor cell apoptosis, tumor growth inhibition, reduced tumor interstitial fluid pressure, and cancer cell hypoxia were observed in treated patients. Pazopanib is a kinase inhibitor. Pazopanib exists in the form of hydrochloride, with the chemical name 5-[[4-[(2, 3-dimethyl span>-2H-indazole-6-yl)methylamino]pyrimidine-2-yl]amino]-2-methylbenzenesulfonamide hydrochloride. Its molecular formula is C21H23N7O2S HCl, and its molecular weight is 473.98 grams/ moles. There are generic drugs in Bangladesh, the retail price of Bangladesh Yaopin International Pharmaceutical200mg30A pillabout 600yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.